Current Issue

Original research

• Sex and authorship in global cancer research (18 April, 2024)

  Miriam Mutebi, Grant Lewison, Deborah Mukherji, Nazik Hammad, Verna Vanderpuye, Erica Liebermann, Winnie K W So, Julie Torode, Richard Sullivan, Ophira Ginsburg
• Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials (11 April, 2024)

  Alexander D Sherry, Pavlos Msaouel, Timothy A Lin, Joseph Abi Jaoude, Ramez Kouzy, Esther J Beck, Avital M Miller, Adina H Passy, Gabrielle S Kupferman, Eugene J Koay, Clifton David Fuller, Charles R Thomas, Zachary R McCaw, Ethan B Ludmir
• Characterisation of clinical response and transcriptional profiling of proliferating CD8 T cells in the blood of cancer patients after PD-1 monotherapy or combination therapy (8 April, 2024)

  Rebecca C Obeng, Tahseen H Nasti, Kylee Martens, Peng Li, Annapaola Mariniello, Daniel Y Chang, Christiane S Eberhardt, Donald McGuire, Haydn Kissick, Candace Daugherty, Yuzi Zhang, Andreas Wieland, Zhengjia Chen, Jeffrey M Switchenko, Rathi Pillai, Alice O Kamphorst, Warren J Leonard, Rafi Ahmed, Suresh S Ramalingam
• Tale of two zones: investigating the clinical outcomes and research gaps in peripheral and transition zone prostate cancer through a systematic review and meta-analysis (3 April, 2024)

  Amin Ali, Thiraviyam Elumalai, BhanuPrasad Venkatesulu, Lauren Hekman, Hitesh Mistry, Ashwin Sachdeva, Pedro Oliveira, Noel Clarke, Esther Baena, Ananya Choudhury, Robert G Bristow
• Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials (19 March, 2024)

  Brody Dennis, Chance Bratten, Griffin K Hughes, Andriana M Peña, Ryan McIntire, Chase Ladd, Brooke Gardner, William Nowlin, Reagan Livingston, Jordan Tuia, Alyson Haslam, Vinay Prasad, Matt Vassar
• Feasibility of implementing a rapid-learning methodology to inform radiotherapy treatments: key professional stakeholders’ views (13 March, 2024)

  Arbaz Kapadi, Gareth Price, Corinne Faivre-Finn, Rebecca Holley, Kate Wicks, Kathryn Banfill, Gareth Webster, Kevin Franks, Fiona McDonald, Daniel Johnson, David P French
• Challenges faced by women oncologists in Africa: a mixed methods study (12 March, 2024)

  Miriam Mutebi, Naa Adorkor Aryeetey, Haimanot Kasahun Alemu, Laura Carson, Zainab Mohamed, Zainab Doleeb, Nwamaka Lasebikan, Nazima Jaffer Dharsee, Susan Msadabwe, Doreen Ramogola-Masire, Sitna Mwanzi, Khadija Warfa, Emmanuella Nwachukwu, Edom Seife Woldetsadik, Hirondina Vaz Borges Spencer, Nesrine Chraiet, Matthew Jalink, Reshma Jagsi, Dorothy Chilambe Lombe, Verna Vanderpuye, Nazik Hammad
• Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review (29 February, 2024)

  Hannah Louise Bromley, Mohini Varughese, Duncan C Gilbert, Peter Hoskin, Ian F Tannock, Kimberley Reeves, Ananya Choudhury
• Accuracy of screening tests for cervical precancer in women living with HIV in low-resource settings: a paired prospective study in Lusaka, Zambia (10 February, 2024)

  Katayoun Taghavi, Misinzo Moono, Mulindi Mwanahamuntu, Marie Roumet, Andreas Limacher, Herbert Kapesa, Thamsanqa Madliwa, Anne Rutjes, Partha Basu, Nicola Low, Albert Manasyan, Julia Bohlius
• Machine learning based on blood test biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy (1 February, 2024)

  Jian-Guo Zhou, Jie Yang, Haitao Wang, Ada Hang-Heng Wong, Fangya Tan, Xiaofei Chen, Si-Si He, Gang Shen, Yun-Jia Wang, Benjamin Frey, Rainer Fietkau, Markus Hecht, Wenzhao Zhong, Hu Ma, Udo Gaipl
• Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending (30 January, 2024)

  Daniel A Goldstein, Leonard B Saltz, Gregory R Pond, Ian F Tannock
• Novel proteomics-based plasma test for early detection of multiple cancers in the general population (9 January, 2024)

  Bogdan Budnik, Hossein Amirkhani, Mohammad H Forouzanfar, Ashkan Afshin